Results 111 to 120 of about 170,012 (267)
Scientific ReportsThe impact of bisphosphonates on cardiac arrhythmia has always been controversial. We aimed to evaluate the risk of bisphosphonates (BPs) on arrhythmia and to characterize the main features of BP-induced arrhythmia by data mining the FDA adverse event ...
Feifei Wang +3 more
doaj +1 more source
Role of selenium in the pathophysiology of cardiorenal anaemia syndrome
ESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai +2 more
wiley +1 more source
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Hepatology Communications, EarlyView., 2022 Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo +19 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi +4 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba +10 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 980-997, April 2025.Abstract Heart failure (HF) creates a considerable clinical, humanistic and economic burden on patients and caregivers as well as on healthcare systems. To attenuate the significant burden of HF, there is a need for enhanced management of patients with HF.
Javed Butler +8 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro +15 more
wiley +1 more source